Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

BACKGROUND: Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited. OBJECTIVES: To evaluate the efficacy and safety of ixekizumab (IXE), a high‐affinity monoclonal antibody that selectively targets interleukin‐17A, for moderate‐to‐severe paediatric p...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, A.S., Seyger, M.M.B., Alejandro Magariños, G., Bagel, J., Pinter, A., Cather, J., Keller, S., Rodriguez Capriles, C., Gontijo Lima, R., Gallo, G., Little, C.A., Edson‐Heredia, E., Li, L., Xu, W., Papp, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496501/
https://www.ncbi.nlm.nih.gov/pubmed/32316070
http://dx.doi.org/10.1111/bjd.19147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496501/
https://www.ncbi.nlm.nih.gov/pubmed/32316070
http://dx.doi.org/10.1111/bjd.19147

Ejemplares similares